Literature DB >> 20414758

Development and in vitro characterization of galactosylated low molecular weight chitosan nanoparticles bearing doxorubicin.

Nitin K Jain1, Sanjay K Jain.   

Abstract

The aim of the present research was to evaluate the potential of galactosylated low molecular weight chitosan (Gal-LMWC) nanoparticles bearing positively charged anticancer, doxorubicin (DOX) for hepatocyte targeting. The chitosan from crab shell was depolymerized, and the lactobionic acid was coupled with LMWC using carbodiimide chemistry. The depolymerized and galactosylated polymers were characterized. Two types of Gal-LMWC(s) with variable degree of substitution were employed to prepare the nanoparticles using ionotropic gelation with pentasodium tripolyphosphate anions. Factors affecting nanoparticles formation were discussed. The nanoparticles were characterized by transmission electron microscopy and photon correlation spectroscopy and found to be spherical in the size range 106-320 nm. Relatively higher percent DOX entrapment was obtained for Gal-LMWC(s) nanoparticles than for LMWC nanoparticles. A further increase in drug entrapment was found with nanoparticles prepared by Gal-LMWC with higher degree of substitution. A hypothesis which correlates the ionic concentration of DOX in nanoparticles preparation medium and percent DOX entrapment in cationic polymer has been proposed to explain the enhanced DOX entrapment. In-vitro drug release study demonstrated an initial burst release followed by a sustained release. The targeting potential of the prepared nanoparticles was assessed by in vitro cytotoxicity study using the human hepatocellular carcinoma cell line (HepG(2)) expressing the ASGP receptors on their surfaces. The enthusiastic results showed the feasibility of Gal-LMWC(s) to entrap the cationic DOX and targeting potential of developed Gal-LMWC(s) nanoparticles to HepG(2) cell line.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20414758      PMCID: PMC2902311          DOI: 10.1208/s12249-010-9422-z

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  41 in total

Review 1.  Drug targeting systems for antiviral agents: options and limitations.

Authors:  D K Meijer; R W Jansen; G Molema
Journal:  Antiviral Res       Date:  1992-06       Impact factor: 5.970

Review 2.  Recent advances on chitosan-based micro- and nanoparticles in drug delivery.

Authors:  Sunil A Agnihotri; Nadagouda N Mallikarjuna; Tejraj M Aminabhavi
Journal:  J Control Release       Date:  2004-11-05       Impact factor: 9.776

3.  Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery.

Authors:  Quan Gan; Tao Wang; Colette Cochrane; Paul McCarron
Journal:  Colloids Surf B Biointerfaces       Date:  2005-08       Impact factor: 5.268

4.  Chitosan-gadopentetic acid complex nanoparticles for gadolinium neutron-capture therapy of cancer: preparation by novel emulsion-droplet coalescence technique and characterization.

Authors:  H Tokumitsu; H Ichikawa; Y Fukumori
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

5.  A simple preparation of half N-acetylated chitosan highly soluble in water and aqueous organic solvents.

Authors:  N Kubota; N Tatsumoto; T Sano; K Toya
Journal:  Carbohydr Res       Date:  2000-03-10       Impact factor: 2.104

6.  Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture.

Authors:  S Bennis; C Chapey; P Couvreur; J Robert
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

7.  Investigation on a novel core-coated microspheres protein delivery system.

Authors:  S Zhou; X Deng; X Li
Journal:  J Control Release       Date:  2001-07-10       Impact factor: 9.776

8.  Blending chitosan with polycaprolactone: effects on physicochemical and antibacterial properties.

Authors:  Aparna R Sarasam; Raj K Krishnaswamy; Sundararajan V Madihally
Journal:  Biomacromolecules       Date:  2006-04       Impact factor: 6.988

9.  Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance.

Authors:  C Cuvier; L Roblot-Treupel; J M Millot; G Lizard; S Chevillard; M Manfait; P Couvreur; M F Poupon
Journal:  Biochem Pharmacol       Date:  1992-08-04       Impact factor: 5.858

10.  Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action.

Authors:  A C de Verdière; C Dubernet; F Némati; E Soma; M Appel; J Ferté; S Bernard; F Puisieux; P Couvreur
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  5 in total

1.  Preparation of Betulinic Acid Galactosylated Chitosan Nanoparticles and Their Effect on Liver Fibrosis.

Authors:  Zi Chao Wu; Xin Yu Liu; Jia Yan Liu; Jing Shu Piao; Ming Guan Piao
Journal:  Int J Nanomedicine       Date:  2022-09-14

2.  Galactosylated Liposomes for Targeted Co-Delivery of Doxorubicin/Vimentin siRNA to Hepatocellular Carcinoma.

Authors:  Hea Ry Oh; Hyun-Young Jo; James S Park; Dong-Eun Kim; Je-Yoel Cho; Pyung-Hwan Kim; Keun-Sik Kim
Journal:  Nanomaterials (Basel)       Date:  2016-07-30       Impact factor: 5.076

3.  Fabrication, characterization, in vitro drug release and glucose uptake activity of 14-deoxy, 11, 12-didehydroandrographolide loaded polycaprolactone nanoparticles.

Authors:  Nagalakshmi Kamaraj; Pooja Yashwanthi Rajaguru; Praveen Kumar Issac; Sujatha Sundaresan
Journal:  Asian J Pharm Sci       Date:  2017-02-27       Impact factor: 6.598

4.  Development and Optimization of Ciprofloxacin HCl-Loaded Chitosan Nanoparticles Using Box-Behnken Experimental Design.

Authors:  Noha M Soliman; Faiyaz Shakeel; Nazrul Haq; Fars K Alanazi; Sultan Alshehri; Mohsen Bayomi; Ahmed S M Alenazi; Ibrahim A Alsarra
Journal:  Molecules       Date:  2022-07-13       Impact factor: 4.927

5.  Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.

Authors:  Xiaoju Zhou; Mengzi Zhang; Bryant Yung; Hong Li; Chenguang Zhou; L James Lee; Robert J Lee
Journal:  Int J Nanomedicine       Date:  2012-10-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.